Short Interest in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Rises By 7.7%

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 119,200 shares, an increase of 7.7% from the November 30th total of 110,700 shares. Currently, 0.7% of the shares of the stock are short sold. Based on an average daily volume of 33,100 shares, the days-to-cover ratio is currently 3.6 days.

Cyclo Therapeutics Trading Down 1.9 %

Shares of NASDAQ CYTH opened at $0.59 on Thursday. The stock has a market cap of $16.97 million, a price-to-earnings ratio of -0.66 and a beta of -0.46. The company’s 50-day moving average price is $0.67 and its 200 day moving average price is $0.87. Cyclo Therapeutics has a 52 week low of $0.55 and a 52 week high of $2.12.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.